Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Alphamab Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. All these matters are situated within 1 distinct art unit, suggesting a highly specialized focus for the current patent applications. These matters are handled by 3 distinct examiners, which means every pending action is being reviewed by a different individual.
CANELLA, KAREN A is identified as the busiest examiner for the portfolio, currently managing 1 pending office action. With 3 distinct examiners assigned to the 3 pending office actions, the prosecution tasks are evenly divided. This lack of examiner concentration within the 1 distinct art unit requires the applicant to address the specific perspectives of 3 different officials.
The busiest examiner, CANELLA, KAREN A, handles only a single pending matter, reflecting the overall distribution where no examiner manages more than 1 pending office action. For a practitioner, the concentration in a single art unit provides a consistent procedural environment, even though the 3 distinct examiners may apply different substantive standards to the Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270097 | HUMAN GLP-1 POLYPEPTIDE VARIANT AND USE THEREOF | NIEBAUER, RONALD T | 60d |
| 18691672 | COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF | CANELLA, KAREN A | — |
| 18014318 | COAGULATION FACTOR XI (FXI) BINDING PROTEIN | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691672 | COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF | CANELLA, KAREN A | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18014318 | COAGULATION FACTOR XI (FXI) BINDING PROTEIN | DAHLE, CHUN WU | — | §102§112DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18270097 | HUMAN GLP-1 POLYPEPTIDE VARIANT AND USE THEREOF | NIEBAUER, RONALD T | 1658 | §103§112DP | Final Rejection | 60d | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial